UCSF has nationally recognized tobacco control researchers whose work has contributed substantially to what is known about nicotine addiction, the effectiveness of legislative and other policies designed to reduce tobacco use, culturally appropriate tobacco control interventions for various subgroups of the population, estimates of the costs to society of tobacco use, and other areas. The Tobacco Control Program brings 18 researchers from nine departments in four schools at UCSF. The Program stimulates plans for collaboration and for the development of shared resources that benefit multiple program members. The goals of the program are: to conduct clinical and laboratory investigations of mechanisms of nicotine addiction that can translate into more effective tobacco cessation methods; to further understand the effects of tobacco use and of exposure to environmental tobacco smoke on risk of various cancers, including studies of genetic markers of susceptibility (gene-tobacco interactions) and investigation of racial/ethnic differences in measures of tobacco exposure and tobacco-related disease risks; to determine effective approaches for tobacco prevention and cessation in defined populations, through controlled trials and through monitoring and surveillance of community-based tobacco control programs; to provide estimates of the economic costs of tobacco use to society; to conduct research on legislative and other tobacco-related policies, including examining the formation and implementation of such policies, analyzing the effectiveness of such policies in reducing use of tobacco and exposure to environmental tobacco smoke, and assessing the quality and dissemination of tobacco-related research; and to document the extent of external medial influences on tobacco use in our society. The Program has $8,250,251 Total peer reviewed support for the last budget year. The Program has 19% intra-programmatic and 11% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-10
Application #
7619915
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
10
Fiscal Year
2008
Total Cost
$74,361
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications